Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials
Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes,...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2010-03, Vol.121 (12), p.1439-1446 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1446 |
|---|---|
| container_issue | 12 |
| container_start_page | 1439 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 121 |
| creator | BÖHM, Michael BAUMHÄKEL, Magnus LISHENG LIU JANSKY, Petr YUSUF, Salim TEO, Koon SLEIGHT, Peter PROBSTFIELD, Jeffrey GAO, Peggy MANN, Johannes F DIAZ, Rafael DAGENAIS, Gilles R JENNINGS, Garry L. R |
| description | Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND).
In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED.
ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101. |
| doi_str_mv | 10.1161/CIRCULATIONAHA.109.864199 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733536072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733536072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-895f0c1f22c5d6e6fcbdb8d06b2645088db2913e868fc3e680a489016ef5ac7f3</originalsourceid><addsrcrecordid>eNpdUl2P0zAQDAjElYO_gMwDAqRrazuNm_AW0tBWqtJTLvccOc6m9ZHExU6Kyq_H_eDgeFp7NDvjXY_jvCd4RAgj42iZRverMFuuk3ARjggORj6bkCB47gyIRyfDiecGL5wBxjgYTl1Kr5zXxjzYK3On3ivnimLqEs9lg2ezWIPoZA1odjBV39qzatGthlKKzqCI61KqPTeir7lG8R5ai8oWLeRmO0yl-Y5ueSdPaAoC5F62G5RB3UjDdcfbG5TyRu60rG-Q0uir6rZfULYFtE426j8uCmvVAuJteXQQqilky0_v-Sm77aMQmteq4DWK23JnJTqUacnr8b9CqdVQjfwFJQqNAWMaSDp01_Xl4SgdRjGSSadq0Nz2m754gOO0JxvxdOSZNMANoE_rJAvTeZyNUZaGyV0UJ7PPZ2vzxnlZ2QJvL_Xauf8WZ9FiuFrPl1G4Ggoa4G7oB16FBakoFV7JgFWiKAu_xKygbOJh3y8LGhAXfOZXwgXmYz7xA0wYVB4X08q9dj6edXda_ejBdLmdWEBd8xZUb_Kp69pPxVNqmcGZKbQyRkOV2801XB9ygvNjhvKnGbJwkJ8zZHvfXVz6ooHysfNPaCzhw4Vgl8Tryi5RSPOXR70pYYy6vwEepNdG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733536072</pqid></control><display><type>article</type><title>Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>BÖHM, Michael ; BAUMHÄKEL, Magnus ; LISHENG LIU ; JANSKY, Petr ; YUSUF, Salim ; TEO, Koon ; SLEIGHT, Peter ; PROBSTFIELD, Jeffrey ; GAO, Peggy ; MANN, Johannes F ; DIAZ, Rafael ; DAGENAIS, Gilles R ; JENNINGS, Garry L. R</creator><creatorcontrib>BÖHM, Michael ; BAUMHÄKEL, Magnus ; LISHENG LIU ; JANSKY, Petr ; YUSUF, Salim ; TEO, Koon ; SLEIGHT, Peter ; PROBSTFIELD, Jeffrey ; GAO, Peggy ; MANN, Johannes F ; DIAZ, Rafael ; DAGENAIS, Gilles R ; JENNINGS, Garry L. R ; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators</creatorcontrib><description>Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND).
In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED.
ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.109.864199</identifier><identifier>PMID: 20231536</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Benzimidazoles - administration & dosage ; Benzoates - administration & dosage ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - drug therapy ; Cardiovascular system ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Double-Blind Method ; Drug Therapy, Combination ; Erectile Dysfunction - epidemiology ; Erectile Dysfunction - etiology ; Humans ; Male ; Medical sciences ; Mortality ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Ramipril - administration & dosage ; Treatment Outcome ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Circulation (New York, N.Y.), 2010-03, Vol.121 (12), p.1439-1446</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-895f0c1f22c5d6e6fcbdb8d06b2645088db2913e868fc3e680a489016ef5ac7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22571662$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20231536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BÖHM, Michael</creatorcontrib><creatorcontrib>BAUMHÄKEL, Magnus</creatorcontrib><creatorcontrib>LISHENG LIU</creatorcontrib><creatorcontrib>JANSKY, Petr</creatorcontrib><creatorcontrib>YUSUF, Salim</creatorcontrib><creatorcontrib>TEO, Koon</creatorcontrib><creatorcontrib>SLEIGHT, Peter</creatorcontrib><creatorcontrib>PROBSTFIELD, Jeffrey</creatorcontrib><creatorcontrib>GAO, Peggy</creatorcontrib><creatorcontrib>MANN, Johannes F</creatorcontrib><creatorcontrib>DIAZ, Rafael</creatorcontrib><creatorcontrib>DAGENAIS, Gilles R</creatorcontrib><creatorcontrib>JENNINGS, Garry L. R</creatorcontrib><creatorcontrib>ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators</creatorcontrib><title>Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND).
In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED.
ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.</description><subject>Angiotensin II Type 1 Receptor Blockers</subject><subject>Angiotensin-Converting Enzyme Inhibitors</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzoates - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular system</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Erectile Dysfunction - epidemiology</subject><subject>Erectile Dysfunction - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Ramipril - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUl2P0zAQDAjElYO_gMwDAqRrazuNm_AW0tBWqtJTLvccOc6m9ZHExU6Kyq_H_eDgeFp7NDvjXY_jvCd4RAgj42iZRverMFuuk3ARjggORj6bkCB47gyIRyfDiecGL5wBxjgYTl1Kr5zXxjzYK3On3ivnimLqEs9lg2ezWIPoZA1odjBV39qzatGthlKKzqCI61KqPTeir7lG8R5ai8oWLeRmO0yl-Y5ueSdPaAoC5F62G5RB3UjDdcfbG5TyRu60rG-Q0uir6rZfULYFtE426j8uCmvVAuJteXQQqilky0_v-Sm77aMQmteq4DWK23JnJTqUacnr8b9CqdVQjfwFJQqNAWMaSDp01_Xl4SgdRjGSSadq0Nz2m754gOO0JxvxdOSZNMANoE_rJAvTeZyNUZaGyV0UJ7PPZ2vzxnlZ2QJvL_Xauf8WZ9FiuFrPl1G4Ggoa4G7oB16FBakoFV7JgFWiKAu_xKygbOJh3y8LGhAXfOZXwgXmYz7xA0wYVB4X08q9dj6edXda_ejBdLmdWEBd8xZUb_Kp69pPxVNqmcGZKbQyRkOV2801XB9ygvNjhvKnGbJwkJ8zZHvfXVz6ooHysfNPaCzhw4Vgl8Tryi5RSPOXR70pYYy6vwEepNdG</recordid><startdate>20100330</startdate><enddate>20100330</enddate><creator>BÖHM, Michael</creator><creator>BAUMHÄKEL, Magnus</creator><creator>LISHENG LIU</creator><creator>JANSKY, Petr</creator><creator>YUSUF, Salim</creator><creator>TEO, Koon</creator><creator>SLEIGHT, Peter</creator><creator>PROBSTFIELD, Jeffrey</creator><creator>GAO, Peggy</creator><creator>MANN, Johannes F</creator><creator>DIAZ, Rafael</creator><creator>DAGENAIS, Gilles R</creator><creator>JENNINGS, Garry L. R</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100330</creationdate><title>Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials</title><author>BÖHM, Michael ; BAUMHÄKEL, Magnus ; LISHENG LIU ; JANSKY, Petr ; YUSUF, Salim ; TEO, Koon ; SLEIGHT, Peter ; PROBSTFIELD, Jeffrey ; GAO, Peggy ; MANN, Johannes F ; DIAZ, Rafael ; DAGENAIS, Gilles R ; JENNINGS, Garry L. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-895f0c1f22c5d6e6fcbdb8d06b2645088db2913e868fc3e680a489016ef5ac7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiotensin II Type 1 Receptor Blockers</topic><topic>Angiotensin-Converting Enzyme Inhibitors</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzoates - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular system</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Erectile Dysfunction - epidemiology</topic><topic>Erectile Dysfunction - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Ramipril - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BÖHM, Michael</creatorcontrib><creatorcontrib>BAUMHÄKEL, Magnus</creatorcontrib><creatorcontrib>LISHENG LIU</creatorcontrib><creatorcontrib>JANSKY, Petr</creatorcontrib><creatorcontrib>YUSUF, Salim</creatorcontrib><creatorcontrib>TEO, Koon</creatorcontrib><creatorcontrib>SLEIGHT, Peter</creatorcontrib><creatorcontrib>PROBSTFIELD, Jeffrey</creatorcontrib><creatorcontrib>GAO, Peggy</creatorcontrib><creatorcontrib>MANN, Johannes F</creatorcontrib><creatorcontrib>DIAZ, Rafael</creatorcontrib><creatorcontrib>DAGENAIS, Gilles R</creatorcontrib><creatorcontrib>JENNINGS, Garry L. R</creatorcontrib><creatorcontrib>ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BÖHM, Michael</au><au>BAUMHÄKEL, Magnus</au><au>LISHENG LIU</au><au>JANSKY, Petr</au><au>YUSUF, Salim</au><au>TEO, Koon</au><au>SLEIGHT, Peter</au><au>PROBSTFIELD, Jeffrey</au><au>GAO, Peggy</au><au>MANN, Johannes F</au><au>DIAZ, Rafael</au><au>DAGENAIS, Gilles R</au><au>JENNINGS, Garry L. R</au><aucorp>ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2010-03-30</date><risdate>2010</risdate><volume>121</volume><issue>12</issue><spage>1439</spage><epage>1446</epage><pages>1439-1446</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND).
In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED.
ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>20231536</pmid><doi>10.1161/CIRCULATIONAHA.109.864199</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2010-03, Vol.121 (12), p.1439-1446 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733536072 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors Benzimidazoles - administration & dosage Benzoates - administration & dosage Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cardiovascular Diseases - diagnosis Cardiovascular Diseases - drug therapy Cardiovascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Double-Blind Method Drug Therapy, Combination Erectile Dysfunction - epidemiology Erectile Dysfunction - etiology Humans Male Medical sciences Mortality Pharmacology. Drug treatments Predictive Value of Tests Ramipril - administration & dosage Treatment Outcome Vasodilator agents. Cerebral vasodilators |
| title | Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/ TRANSCEND) Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A31%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erectile%20Dysfunction%20Predicts%20Cardiovascular%20Events%20in%20High-Risk%20Patients%20Receiving%20Telmisartan,%20Ramipril,%20or%20Both:%20The%20ONgoing%20Telmisartan%20Alone%20and%20in%20combination%20with%20Ramipril%20Global%20Endpoint%20Trial/Telmisartan%20Randomized%20AssessmeNt%20Study%20in%20ACE%20iNtolerant%20subjects%20with%20cardiovascular%20Disease%20(ONTARGET/%20TRANSCEND)%20Trials&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=B%C3%96HM,%20Michael&rft.aucorp=ONTARGET/TRANSCEND%20Erectile%20Dysfunction%20Substudy%20Investigators&rft.date=2010-03-30&rft.volume=121&rft.issue=12&rft.spage=1439&rft.epage=1446&rft.pages=1439-1446&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIRCULATIONAHA.109.864199&rft_dat=%3Cproquest_cross%3E733536072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733536072&rft_id=info:pmid/20231536&rfr_iscdi=true |